Navigation Links
Hope for patients with Chronic leukemia

For the first time in India ,German Remedies, a part of the Zydus group, has launched Fludara Oral (fludarabine) for the treatment // of chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia (CLL) is a cancer of the lymphocytes. It is a serious, progressive disease, which at present has no cure. The disease is unknown in childhood, very uncommon in young people and becomes progressively more common with increasing age.

Fludarabine has emerged as one of the leading drugs for treatment of CLL, and can be used as a stand –alone therapy or as a combination therapy. It helps control CLL by shortening the life-span of existing leukemia cells and interferes with the making of new DNA, thus preventing leukemia cells from growing. With this treatment the remission can last for several years, thereby increasing the span of survival.

Executive director of German Remedies has been cited as saying that their main goal is to improve the quality of life for the patients and enable better disease management especially in the field of Oncology, their company’s core therapy area., Chronic lymphocytic leukemia, India, German remedies, zydus, patients, fludara oral, fludarbine, CLL, lymphocytes, cancer, disease, therapy, leukemia cells, DNA, oncolog.
'"/>




Page: 1

Related medicine news :

1. HIV infected patients can travel safely abroad
2. New vaccine helps allergy and asthma patients
3. Doctors operate upon patients in candlelight- latest from the quake scene
4. New vaccine helps allergy and asthma patients
5. Are cancer patients being taken for a ride?
6. Alternative medicine more popular among HIV positive patients
7. ATG useful in transplant patients as substitute for steroids
8. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
9. Distraction therapy found very effective in postoperative patients
10. Cancer patients turning to Internet for information
11. Helping stroke patients to recover balance
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... stories, courtesy of leaders in the nursing and health care industry. It also ... advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... Florida (PRWEB) , ... May 26, 2016 , ... ... House® Project offering a new model of care for living and healing, celebrated ... core values: Meaningful Life in a Real Home provided by Empowered Staff. , “This ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: